{"entity":{"id":"nct07662811","kind":"trial","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2/3 trial of carboplatin, nab-paclitaxel and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","summary":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07662811 by Shanghai Chest Hospital, with a registry enrolment figure of 396 participants, started 2026-06-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: SYHX2011; Carboplatin; Enlonstobart; Nab-Paclitaxel; Carboplatin; Tislelizumab. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR) for phase II; Progression Free Survival (PFS) for phase III. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced or metastatic squamous non-small cell lung cancer (Stage IIIB, IIIC, or IV according to the IASLC 9th Edition TNM Staging System), ineligible for radical surgery and/or radical radiotherapy\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07662811","url":"https://clinicaltrials.gov/study/NCT07662811"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-squamous-cell-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","nab-paclitaxel","tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07662811","phase":"2/3","setting":"SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II/III Study","sponsor":"Shanghai Chest Hospital","enrolled":396,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07662811/","neighbours":{"cancer":[{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}